OpenAI has acquired Orchestra Bio and will integrate it into its Rosalind life-sciences platform. The companies aim to build AI agents that track clinical trials, flag delays and propose next steps, potentially shortening a US drug-development process that averages 10–15 years. Deal terms were not d